DBV Technologies company profile
Company profile
DBV Technologies has 179 employees and is headquartered in Châtillon, France.
Viaskin Peanut, an epicutaneous immunotherapy product for peanut allergy, has completed a Phase 3 clinical trial, while Viaskin Milk, aimed at cow's milk protein allergy and eosinophilic esophagitis, is in Phase 1/2 trials. The company also runs earlier-stage research into celiac disease and develops the Viaskin technology platform, which is designed to potentially treat food allergy. Its collaboration with Nestlé Health Science covers MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers.
In the fiscal year ended December 2025, DBV Technologies reported revenue of USD 5.6 million, up 35.8% on the previous year, and a net loss of USD 146.9 million. Its research and development is carried out in France. The company had 179 employees and is headquartered in Châtillon, France; it was incorporated in 2002.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Headquarters
- BAtiment IRO, 92320, Châtillon
- Employees
- 179
- Chief executive
- Daniel Tassé
- Founded
- 2002
- Fiscal year
- January - December
- Listing
- DBV · Euronext Paris
- Currency
- EUR
- ISIN
- FR0010417345
- Website
- dbv-technologies.com
DBV Technologies and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| DBV TechnologiesDBV | France | $572.52M | 179 | -5,577.0% | — |
| GubraGUBRA | Denmark | $730.02M | 330 | -73.1% | — |
| Pharming GroupPHARM | Netherlands | $841.25M | 407 | 12.8% | 36.1 |
| InventivaIVA | France | $890.8M | 87 | -5,980.9% | — |
| PhilogenPHIL | Italy | $905.96M | 230 | 79.1% | 3.67 |
| Basilea PharmaceuticaBSLN | Switzerland | $1.07B | 200 | 24.2% | 18.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
